Simcere breaks negative trend for Chinese listings in the US

The pharmaceutical company trades up 5.5% after pricing its $226.5 million IPO at the top of the range.

Simcere Pharmaceutical Group has broken the recent trend of a negative first day performance for Chinese companies listing in the US, rising 5.5% on its New York Stock Exchange trading debut on Friday.

The company, which manufactures and distributes mainly branded generic pharmaceuticals but has also made a move into innovative drugs, received a good response to its initial public offering, allowing it to fix the price at the top of the $12.50 to $14.50 range.

This resulted in...

To continue reading, please login or register for free

Click for more on: ipo | nyse | pharmaceuticals | goldman sachs

Print Edition

FinanceAsia Print Edition


  • 2nd Compliance Summit Southeast Asia

    17 August 2017  |  Singapore
    The 2017 Compliance Summit Southeast Asia will take an in-depth look at the key compliance considerations today with a focus on regulation and new ...